Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models

被引：0
作者：
Ryotaro Teranaka
Hiroshi Fujimoto
Takahito Masuda
Masayuki Kuroda
Yasuyuki Aoyagi
Takeshi Nagashima
Mamoru Takada
Junta Sakakibara
Hideyuki Yamada
Hiroto Yamamoto
Yoshitaka Kubota
Masayuki Ohtsuka
机构：
[1] Chiba University Graduate School of Medicine,Department of General Surgery
[2] Chiba University Hospital,Center for Advanced Medicine
[3] CellGenTech,Department of Plastic, Reconstructive, and Aesthetic Surgery
[4] Inc.,undefined
[5] Chiba University Graduate School of Medicine,undefined
来源：
Breast Cancer | 2023年 / 30卷
关键词：
Breast cancer; Adipocytes; Gene therapy; Human epidermal growth factor receptor 2; Molecular target therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1018 / 1027
页数：9
相关论文
共 50 条
  • [11] Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
    Kuo, Wei-Ying
    Hsu, Hung-Ju
    Wu, Chun-Yi
    Chen, Hong-Sen
    Chou, Yu-Chi
    Tsou, Yueh-Liang
    Peng, Hung-Pin
    Jian, Jhih-Wei
    Yu, Chung-Ming
    Chiu, Yi-Kai
    Chen, Ing-Chien
    Tung, Chao-Ping
    Hsiao, Michael
    Lin, Chia-Lung
    Wang, Yong Alison
    Wang, Andrew H-J.
    Yang, An-Suei
    MABS, 2019, 11 (01) : 153 - 165
  • [12] Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
    Xie, Yifan
    Wu, Siyu
    Zhang, Ying
    Li, Jianwei
    Mo, Miao
    Shao, Zhimin
    Liu, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [13] Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo
    Han, Huamin
    Ma, Juan
    Zhang, Keming
    Li, Wei
    Liu, Changzhen
    Zhang, Yu
    Zhang, Ganlin
    Ma, Pan
    Wang, Lei
    Zhang, Ge
    Tao, Hua
    Gao, Bin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (06) : 2446 - 2454
  • [14] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [15] Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models
    Shiravi, Fariba
    Mohammadi, Mehdi
    Golsaz-Shirazi, Forough
    Bahadori, Tannaz
    Judaki, Mohammad Ali
    Fatemi, Forough
    Zare, Hengameh Ahmadi
    Haghighat, Farzaneh Notash
    Mobini, Maryam
    Jeddi-Tehrani, Mahmood
    Amiri, Mohammad Mehdi
    Shokri, Fazel
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 697 - 704
  • [16] A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
    Anja Kathrin Wege
    Nicole Kirchhammer
    Linda Veronique Kazandjian
    Sandra Prassl
    Michael Brandt
    Gerhard Piendl
    Olaf Ortmann
    Stephan Fischer
    Gero Brockhoff
    Journal of Translational Medicine, 18
  • [17] Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
    Bradbury, Michelle
    Savard, Marie-France
    Vandermeer, Lisa
    Clemons, Lucas
    Pond, Gregory
    Hilton, John
    Clemons, Mark
    Mcgee, Sharon
    CURRENT ONCOLOGY, 2023, 30 (12) : 10477 - 10487
  • [18] A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
    Wege, Anja Kathrin
    Kirchhammer, Nicole
    Kazandjian, Linda Veronique
    Prassl, Sandra
    Brandt, Michael
    Piendl, Gerhard
    Ortmann, Olaf
    Fischer, Stephan
    Brockhoff, Gero
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [19] Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
    de Azambuja, E.
    Agostinetto, E.
    Procter, M.
    Eiger, D.
    Ponde, N.
    Guillaume, S.
    Parlier, D.
    Lambertini, M.
    Desmet, A.
    Caballero, C.
    Aguila, C.
    Jerusalem, G.
    Walshe, J. M.
    Frank, E.
    Bines, J.
    Loibl, S.
    Piccart-Gebhart, M.
    Ewer, M. S.
    Dent, S.
    Plummer, C.
    Suter, T.
    ESMO OPEN, 2023, 8 (01)
  • [20] Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
    Nahleh, Zeina A.
    Elimimian, Elizabeth B.
    Elson, Leah C.
    Hobbs, Brian
    Wei, Wei
    Blake, Cassann N.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2020, 14
12345